ABSTRACT BACKGROUND Recent trials of fish oil for the prevention of atrial fibrillation (AF) recurrence have provided mixed
STUDY POPULATION. Eligible patients were those 18 years of age and older with a history of documented, symptomatic paroxysmal or persistent AF lasting $10 min within 6 months of enrollment, who had a rhythm-control strategy planned by the treating physician. Major exclusion criteria were AF continuously present for $3 months, the need for continued class I or III AA therapy, New York Heart Association functional class III-IV heart failure, left ventricular ejection fraction <40%, known secondary cause of AF (e.g., hyperthyroidism, fever, anemia, postoperative AF), and the use of n-3 PUFA supplements within 3 months of enrollment. Placebo capsules consisted of 1 g of safflower oil.
Safflower oil is free of n-3 PUFAs and has no purported AA effects. Given the pharmacokinetic profile of EPA þ DHA after long-term ingestion (13, 14) , a 3-week loading phase represented a balance between adequate incorporation of n-3 PUFAs into biological tissues permitting potential AA effects and achieving a steady state for maximal efficacy. Therefore, treatment began at enrollment, with patients first entering a 3-week loading/blanking phase and then a follow-up phase beginning on day 22. Patients not in sinus rhythm on day 21 were required to undergo cardioversion; failed cardioversion was considered an AF recurrence. Patients were followed for 6 to 16 months. Patients who had an AF recurrence before 6 months were followed until the 6-month study visit, with class I or III AA therapy permitted after the first recurrence. Patients without AF recurrence at 6 months were followed until the first AF recurrence or for 16 months.
Recurrence of AF was monitored by weekly transtelephonic monitor transmissions to detect potentially asymptomatic episodes, whereas symptomatic episodes were assessed by transtelephonic monitor strips, 12-lead electrocardiography or any implanted device. The omega-3 index, representing the erythrocyte membrane content of EPA þ DHA as a percent of total membrane fatty acids, was used as a measure of adherence to study medication and performed at baseline and at AF recurrence or the 6-month visit, whichever occurred first. 
RESULTS
A total of 337 patients were randomized, of whom 297 (88%) completed the study ( Figure 2 ). Subjects not completing the study were distributed equally in both groups and related primarily to withdrawal of consent (30%) and nonserious adverse events (28%). Baseline demographic, clinical, and cardiac characteristics and medication were similar between treatment groups ( Table 1) .
PRIMARY OUTCOME MEASURE. The overall rate of AF recurrence was high (63.6%) but did not differ between groups (Central Illustration, Table 2 ). Furthermore, the number of days in follow-up, percent of asymptomatic episodes, and number of AF relapses at 6 months were similar between groups. Results were consistent across all subgroups, except for a significantly higher AF recurrence for fish oil users with any ischemic heart disease (hazard ratio: 2.6; 95% confidence interval: 1.1 to 6.1); however, the absolute numbers were small, and the multiple testing suggests that this association is likely spurious (Figure 3) . SECONDARY OUTCOME MEASURES. MPO and hs-CRP were similar between groups at baseline and were within normal limits ( Table 3) . Values of both markers decreased modestly over 6 months for all patients, although no significant treatment Â time interaction was noted. Nigam et al.
Fish Oil and Atrial Fibrillation Recurrence confidence interval: À0.3 to 13.2) and was primarily related to hospitalizations for AF (10 vs. 7 patients in the fish oil and placebo groups, respectively; p ¼ 0.4).
Study medication was generally well tolerated.
Only 17 patients (10 placebo, 7 fish oil) experienced an adverse event leading to discontinuation of study medication. Of these events, 11 (6 placebo, 5 fish oil)
were deemed related to study treatment, primarily gastrointestinal side effects.
OMEGA-3 INDEX. As expected, the omega-3 index was similar between groups at baseline and was significantly increased in the fish oil group relative to the placebo group during follow-up ( Figure 4) . However, the index did not differ between patients with and without AF recurrence at 6 months, irrespective of treatment group. Furthermore, the change in omega-3
index from baseline was also not associated with a higher or lower risk of AF recurrence (data not shown).
DISCUSSION
Our study demonstrates that high-dose, long-chain n-3 fatty acids do not reduce symptomatic or asymptomatic AF recurrence or the number of recurrences over a follow-up period of up to 16 months among patients with paroxysmal or persistent AF not receiving conventional AA therapy (Central Illustration). Importantly, fish oil at the dose used also had no impact on hs-CRP or MPO, suggesting that although both inflammation and oxidative stress may be implicated in the pathophysiology of AF, fish oil had no effect on either mechanism, which may explain its lack of efficacy.
To date, randomized trials of fish oil for the prevention of AF recurrence have provided mixed, generally negative results (8) (9) (10) (11) (12) . The AFFORD is comparable to the 2 largest studies with respect to sample size and methodology (8, 9) . In the first Omega-3 fatty acids are known to reduce systemic inflammation and oxidative stress (18, 19) ; both mechanisms contribute to atrial remodeling and both the initiation and recurrence of AF (20, 21) . In our study, hs-CRP was not elevated at baseline (mean Values are n (%), mean AE SD, or mean (minimum, maximum). *Only for patients with a recurrence.
AF ¼ atrial fibrillation.
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Fish Oil and Atrial Fibrillation Recurrence value, w2 mg/dl), and decreased modestly in both groups. Similarly, MPO was within normal limits at baseline and decreased slightly in both groups (Table 3) . Our findings raise 2 potential hypotheses. STUDY LIMITATIONS. Potential limitations of the current study include the formulation of n-3 PUFA supplements used. Fish oil capsules contained EPA and DHA in a 2:1 ratio, whereas certain data suggest that DHA may have greater AA properties than EPA (6, 21, 23, 24) . However, this ratio was protective against sudden arrhythmic death in the GISSIPrevenzione study (25) . Second, participants were not fitted with implantable loop recorders that, although costly and invasive, would have, in theory, provided the optimal means for detection of AF recurrence. As a more cost-effective alternative, patients had transtelephonic monitors, allowing them to transmit rhythm strips at will. Again, previous trials of fish oil for the prevention of AF recurrence generally used 12-lead electrocardiography or 24-h Holter monitors to detect recurrent episodes. Third, we did not assess the potential impact of fish oil in combination with either AADs or following AF ablation.
However, as noted previously and in contrast to previously mentioned studies (9) (10) (11) (12) , the specific purpose of the AFFORD was to evaluate the efficacy of fish oil as the sole AA agent in a group of low-risk patients.
Additionally, data on the efficacy of fish oil after AF ablation are very limited, with 1 small, nested case-control study suggesting some benefit (26).
Fourth, although we observed a trend toward a higher risk of cardiovascular death or hospitalization in the fish oil group, we believe this association to be spurious due to small numbers and multiple testing.
Again, most of these endpoints were hospitalizations for AF recurrence. Furthermore, previous studies in AF (8) (9) (10) (11) (12) and large studies in coronary heart disease (25, 27) have not shown fish oil to be associated with a higher risk of death, but suggest that it may even be protective (25) . Finally, we made no effort to control for dietary sources of omega-3 fatty acids and no dietary counseling was provided to participants. Although certain macronutrients, including omega-6 fatty acids, refined sugars, and processed meats, are known to be pro-inflammatory (28-30) and therefore could potentially influence hs-CRP, given the randomized nature of the study and sample size, a significant diet Â treatment group interaction is unlikely.
CONCLUSIONS
Among low-risk patients with paroxysmal or persistent AF not receiving conventional AA therapy, fish oil used at a higher dose than in most previous studies does not reduce symptomatic or asymptomatic AF recurrence. Furthermore, fish oil at the dose used did not lower systemic markers of inflammation and oxidative stress. The lack of a beneficial effect of fish oil on AF recurrence in the AFFORD may be at least partially due to its lack of effect on these pathophysiological processes, which have been implicated in AF development and progression.
We believe that our results provide conclusive evidence that fish oil has no role in the rhythm-control management of patients with paroxysmal or persistent AF.
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